Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.33 |
| ▸ | PARP1 | P09874 | 1/20 | 0.30 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.30 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15984749 | 0.74 | PDK1 (0.39) | HAVCR2PARP1PARP15PARP3 | |
| SCHEMBL21888964 | 0.74 | PDK1 (0.39) | HAVCR2PARP1PARP15PARP3 | |
| SCHEMBL23732125 | 0.71 | HAVCR2 (0.36) | HAVCR2 | |
| SCHEMBL23732014 | 0.68 | NR2E1 (0.36) | HAVCR2PARP1PARP15PARP3 | |
| SCHEMBL19662567 | 0.66 | NOS3 (0.37) | HAVCR2 | |
| SCHEMBL17146831 | 0.66 | — | — | |
| SCHEMBL2190670 | 0.64 | — | — | |
| SCHEMBL171272 | 0.64 | HAVCR2 (0.48) | HAVCR2PARP1PARP15PARP3 | |
| SCHEMBL2756447 | 0.64 | — | — | |
| SCHEMBL10281378 | 0.62 | HAVCR2 (0.47) | HAVCR2PARP1PARP15PARP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6984646-B2 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALHCARE AG (DE) | 2006-01-10 | — | — | US | disclosed |
| EP-1412353-B1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2005-03-02 | — | — | EP | disclosed |
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | BAYER HEALTHCARE AG (DE) | 2004-11-04 | — | — | US | disclosed |
| EP-1412353-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | Bayer HealthCare AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| WO-2003008413-A1 | IMIDAZOPYRIDINONES AS P38 MAP KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040220208-A1 | Imidazopyridinones as p38 map kinase inhibitors | MAPK1, MAPK3, MAP3K1 | HAVCR2 2866/4885PARP1 931/4885PARP15 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.